|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
|
|
|
Dr. Mark Mitchnick, CEO of Particle Sciences and CMO of Lubrizol, discusses the rise of complex drug products, the capabilities needed to develop and manufacture these products, and the company’s expansion in this area.
|
|
|
Tom Quinci, MSc, believes oncology requires new treatment modalities that are better for patients, and it is time technologies like drug-eluting implants, offering real, achievable advantages, are more widely considered.
|
|
|
Liliana Miinea, PhD, says with certain polymers, it is possible for drug formulators to take full advantage of the benefits of ASDs, enabling them to overcome formulation challenges to deliver more effective novel drug products capable of transforming the lives of patients.
|
|
|
This 30-page eBook is exactly what you have been looking for. Find out what is driving the lyophilization market and how working with a CDMO will save time and money and help you comply with increasing regulatory requirements.
|
|
|
|
|
|
|
|
|

Specializing in lentiviral and retroviral vectors, Genezen offers early-phase process development, GMP vector production, analytical testing services and assay development. Leveraging the expansive knowledge and experience of its team, Genezen accelerates cell and gene therapies to commercialization and helps deliver life-changing therapeutics to patients. Founded in 2014, the company strives to make viral vector production accessible to early-stage, growth-oriented companies and established industry leaders. Genezen operates out of a 75,000-square-foot, state-of-the-art, cGMP-compliant lentiviral and retroviral vector production facility. Situated in the fast-growing life sciences hub of Indianapolis, the laboratory is the second phase of a larger cGMP-compliant lentiviral and retroviral vector production facility, which will house multiple cGMP production suites with capabilities for host cell expansion and banking and viral vector production. Click here for more.
|
|
|
|
|
|
 |
|
Acumen Pharmaceuticals, Inc. recently announced the completion of enrollment in its Phase 1 INTERCEPT-AD trial of ACU193 in patients with early Alzheimer’s disease…..
|
|
 |
|
Company increases laboratory capacity to meet customer demand for fully integrated drug development capabilities….
|
|
 |
|
The partnership will combine Gerresheimer’s extensive glass converting expertise with Corning’s Velocity® Vial technology platform, helping set a new standard for the industry….
|
|
 |
|
Evaxion Biotech A/S and Pantherna Therapeutics GmbH recently announced preclinical proof of concept for the combination of the two companies’ key….
|
|
 |
|
Nectin Therapeutics Ltd. recently announced it has entered into a clinical trial collaboration agreement with Merck. Under this collaboration, Nectin will evaluate the safety, tolerability, and antitumor activity of its novel….
|
|
|
|
|
|
|
|
 |
|
Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …
|
|
 |
|
Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …
|
|
 |
|
By: Thomas Otto, Managing Director, Vetter
As we come to the end of another year, our global economy faces many significant challenges. Recently, a colleague asked me, “As a biopharma executive, which of today’s major issues are the ones that …
|
|
 |
|
Soft mist inhalers (SMIs) are a versatile technology suitable for the delivery of both small and complex large molecules, optimising lung deposition whilst minimising oropharyngeal deposition.
The Resyca® SMI is a joint venture between Recipharm and Medspray that harnesses …
|
|
 |
|
Manufacturing Phase 1 clinical material in as little as 12–16 months
Traditionally, early-stage and late-stage process development have been done separately, with early-stage mostly focused on material production and late-stage on process intensification. As more molecules in development fall under …
|
|
|
|
|
Upcoming eNewsletter Features:
February 22 – ODT/Fast Dissolve
March 1 – Drug Delivery
|
|
|
|
|
|
|
|